The application of disease-regulated promoters in local gene therapy for rheumatoid arthritis potentiates the development of a sophisticated treatment that relies on a restricted and fine-tuned supply of biologicals. Although several studies have investigated regulated promoters for achieving effective transgene expression during arthritis, none have explored their potential for minimizing deleterious effects arising from constitutive overexpression of transgenes under naive conditions. Using naive and collagen-induced arthritic mice, we examined the applicability of a hybrid interleukin-1 enhancer/interleukin-6 proximal promoter for achieving efficacious murine interleukin-4 gene therapy under arthritic conditions, while minimizing interleukin-4-induced inflammation under naive conditions. We found strong upregulation of transgene expression in virally transduced knee joints under arthritic conditions compared to levels in naive animals. Besides its responsiveness, the promoter strength proved sufficient for generating therapeutically efficacious levels interleukin-4, as demonstrated by the successful protection against cartilage erosion in collagen-induced arthritis. Most importantly, promoter-mediated restriction of the potent chemotactic interleukin-4 in naive animals strongly reduced the amounts of inflammatory cell influx. This study suggests the suitability of the interleukin-1 enhancer/interleukin-6 proximal promoter for the development of a local gene therapy strategy for rheumatoid arthritis that requires finetuned and restricted expression of transgenes with a pleiotrophic nature.
Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune disease that mainly affects synovial joints and which is characterized by inflammatory synovitis, ultimately leading to invasion and destruction of articular cartilage and bone. 1, 2 Rather than a continuous clinical course, RA displays variable disease activity in a considerable fraction of patients resulting in spontaneous remissions and exacerbations of joint inflammation. 3 Although the etiology of RA remains to be elucidated, it is recognized that the proinflammatory cytokines tumor necrosis factor a (TNF-a) and interleukin-1 (IL-1) are central mediators of inflammation and cartilage destruction, respectively. 4 Conventional treatments for RA are predominantly based on systemic delivery of biologicals that target these proinflammatory cytokines, for example anti-TNF-a. 5 Although these treatments have shown to be therapeutically efficacious, the safety of the systemic mode of treatment is under dispute. 6, 7 Local intraarticular gene therapy represents a promising alternative for coping with side effects and improving therapeutic efficacy. The joint resident cells, primarily synovial fibroblasts, are readily transduced by several viral vectors and potentially sustain long-term gene expression from both integrating and non-integrating vectors. [8] [9] [10] As demonstrated in animal models, the relatively confined joint space appears ideally suited for treatments relying on secretion of anti-inflammatory proteins such as IL-4, IL-10 or IL-1 receptor antagonist. 11 A strong advantage of gene therapy is the possibility to transcriptionally control transgene expression and effectuating protein supply that is restricted to arthritic conditions. [12] [13] [14] [15] Moreover, by minimizing transgene expression under naive conditions, a safer mode of gene therapy could be generated that allows the application of biologicals, which have deleterious effects when expressed constitutively, such as IL-4.
Intra-articular IL-4 gene therapy has been demonstrated to prevent cartilage and bone erosion in experimental arthritis. [16] [17] [18] [19] The anti-inflammatory capacity of IL-4 arises from its capacity to downregulate the production of proinflammatory and Th1 cytokines by inducing mRNA degradation and upregulating expression of inhibitors of proinflammatory cytokines. Reduction of Th1 cytokines results in suppression of macrophage activation and production of IL-1, IL-6, IL-8 and TNF-a. 20 In contrast to the annotated anti-inflammatory properties, IL-4 is also potent proinflammatory and chemotactic factor for fibroblasts and macrophages. 20, 21 This is illustrated by the fact that overexpression of IL-4 in a naive knee joints results in a severe joint inflammation that is characterized by synovial cell influx. 18 In this study, we investigate whether controlled and temporal expression of IL-4 minimizes these side effects.
Results

IL-1E/IL-6P promoter is responsive to collagen-induced arthritis
Previously, we have shown that the hybrid IL-1E/IL-6P promoter, composed of the human interleukin-1 enhancer region (À3690/À2720) upstream of the human interleukin-6 proximal promoter (À163/+12), responds to a broad range of proinflammatory cytokines in vitro as well as to an acute joint inflammation induced by zymosan or streptococcal cell wall material. 13, 14 Alternatively, we investigated the responsiveness of this hybrid promoter to collagen-induced arthritis, which is an animal model of arthritis that is characterized by immune-mediated polyarticular joint inflammation and irreversible cartilage damage. To this end, adenovirus-(10 7 ffu) expressing IL-1E/IL-6P-driven luciferase was injected into either nonaffected or arthritic knee joints of collagen type II immunized DBA/1J mice. Luciferase activities in the synovium were measured at 2 or 7 days after virus injection. Under naive conditions, the basal promoter activities were low (1.0 Â 10 3 RLU, not shown), in line with previous observations. 13, 14 When arthritis developed at 2 and 7 days after virus injection, luciferase activity was strongly increased (3.0 Â 10 4 RLU) ( Figure 1 ). As we described previously, 22 the transduction efficiency of the synovial tissue in arthritic joints was hampered. Still, luciferase activities were significantly increased over basal levels at day 2 and 7, although fiveto sixfold lower (5-6 Â 10 3 RLU) than activities observed in joints that were noninflamed at transduction. This shows a strong response of the IL-1E/IL-6P promoter to an immune-mediated inflammation. Furthermore, the IL-1E/IL-6P promoter activity was to the same extent at day 2 and 7, which illustrates that the promoter is not shut down when disease persists. This marks a strong advantage over the conventionally applied constitutively active viral promoters, such as the cytomegalovirus (CMV) immediate-early promoter, which gives rise to a short expression peak at 2 days after transduction that is strongly declined after 7 days. 13, 14 Murine IL-4 does not influence IL-1E/IL-6P promoter activity in vitro It has been reported that IL-4 synergizes with IL-1 in the release of several factors, for example IL-6, from fibroblasts, [23] [24] [25] but there is also evidence pointing to a suppressive effect of IL-4 on IL-1-induced secretion of matrix metalloproteinases. 26, 27 From previous studies it was determined that IL-1 and lipopolysaccharide (LPS) strongly upregulate IL-1E/IL-6P promoter activity; 13 therefore, we sought to investigate whether expression of murine IL-4 might interfere with the inducibility of IL-1E/IL-6P promoter activity. To this end, murine 3T3 fibroblasts were infected with Ad5.IL-1E/IL-6P-Luc at a multiplicity of infection of 50. The day thereafter, cells were stimulated for 24 h with recombinant murine IL-4 (5 or 50 ng ml À1 ) in the absence or presence of IL-1a (10 ng ml À1 ) or LPS (2 mg ml À1 ) (Figure 2 ). IL-4 alone did not affect promoter activity; relative expression levels were 9773 and 10475 for 5 and 50 ng ml À1 IL-4, respectively. The proinflammatory stimuli IL-1a or LPS alone increased promoter activity approximately four-to fivefold, expression levels were 524716 and 455721, respectively. Addition of IL-4 resulted in neither additive nor suppressive effects on LPS-induced promoter activity. IL-4 showed a slightly suppressive, but nonsignificant, effect on IL-1a-induced promoter activity. These results indicate that IL-4 does not influence basal or Disease-regulated IL-4 gene therapy for arthritis J Geurts et al induced IL-1E/IL-6P promoter activity. It is expected that IL-1E/IL-6P-driven IL-4 expression in vivo will depend primarily on the presence of proinflammatory mediators rather than IL-4 itself.
Disease-regulated IL-4 expression prevents cartilage erosion in collagen-induced arthritis
Previously, we have shown that intra-articular overexpression of murine IL-4 provides protection against progression to major cartilage erosion in collageninduced arthritis, presumably by suppression of IL-1b expression and nitric oxide synthesis. 18 To demonstrate that IL-1E/IL-6P-driven mIL-4 expression levels are therapeutically efficacious, 10 7 ffu Ad5.CMV-mIL-4 (positive control, constitutive IL-4 expression), Ad5.dl70-3 (negative control, no IL-4 production), or Ad5.IL-1E/IL-6P-mIL-4 were injected in the knee joints of collagen type II immunized DBA-1/J mice, 2 days after they received a collagen booster injection. At day 30, incidence of arthritis was 100% in both IL-4 groups and 80% in the control group. As described previously for this vector dose, 18 there were no significant differences between IL-4-treated and control groups in macroscopic clinical score of arthritis and histological score of inflammation (data not shown). Consecutively, histological knee joint sections were scored for cartilage depletion and cartilage surface erosions in the patella and femur region ( Figure 3a ). Profound proteoglycan depletion was observed in all groups, sustaining evidence that mIL-4 has no protective effect on cartilage proteoglycan depletion (data not shown). However, mIL-4-expression led to a significant decrease in erosion of patellar and femoral cartilage as compared to the control group (Figure 3b ). Whereas femoral cartilage was severely eroded (mean 2.670.3) in the control group, constitutive or disease-regulated expression of mIL-4 in arthritic mice revealed non-(CMV) or mildly eroded femoral cartilage (IL-1E/IL-6P: 0.670.2). Patellar cartilage was less severely eroded than femoral cartilage in the control group (1.170.2 out of 3.0); however, the same trend of cartilage protection was observed in both IL-4-treated groups (CMV: 0.0370.03, IL-1E/IL-6P: 0.370.1). This experiment proved that the IL-1E/IL-6P promoter activity in arthritic animals is sufficient to provide therapeutically efficacious mIL-4 levels.
IL-1E/IL-6P-driven IL-4-expression results in marginal inflammation in naive mice
Previously, it was demonstrated that constitutive intraarticular overexpression of mIL-4 for 7 days leads to substantial joint inflammation, characterized by massive infiltration of cells into the synovial cavity (exudate) and synovial tissue (infiltrate). 18 We hypothesize that diseaseregulated mIL-4 expression will lead to low levels of mIL-4 under naive conditions, thereby substantially reducing cell influx in naive mice. To verify this hypothesis, Ad5.IL-1E/IL-6P-mIL-4, Ad5.CMV-mIL-4 or Ad5.dl70-3 (10 7 ffu) was injected in the knee joints of naive C57Bl/6 mice. Eight days after viral transduction mIL-4 levels were measured in patella washouts. Production of mIL-4 in mice treated with control adenovirus was below the detection limit (o5 pg ml À1 ), which demonstrates that endogenous IL-4 levels in the joint are low. Driving IL-4 expression by the IL-1E/IL-6P promoter resulted in low basal levels (8.473.0 pg ml À1 ) as compared to those obtained with the CMV promoter (41000 pg ml
À1
). Next, histological knee joints sections at day 7 were inspected for the presence of infiltrate and exudate ( Figure 4a ). As expected, constitutive expression of IL-4 for 7 days generated massive joint inflammation 
Discussion
The concept of applying disease-regulated promoters in gene therapy for arthritis is a scarcely explored field. Nevertheless, this strategy contains a large potential since it might provide a fine-tuned supply of therapeutic proteins in an offer meets demand fashion. Perhaps even more importantly, tight control of transgene expression potentially minimizes the risk of deleterious effects under nondiseased conditions, such as toxicity or immune responses. This however, has not been investigated so far; similar studies focused rather on effective transgene expression under arthritic conditions. 12, [28] [29] [30] In this study, we demonstrate for the first time that disease-regulated mIL-4 expression by the IL-1E/IL-6P promoter provides not only therapeutically efficacious protein levels under arthritic conditions, but also sufficiently low activity under naive conditions. Minimizing the undesired effects of biologicals, in this case the potent proinflammatory and chemotactic properties of IL-4, requires promoters with low basal activity under naive conditions. Promoter regions from acute phase proteins (APP), [28] [29] [30] [31] [32] [33] inducible nitric oxide synthase (iNOS), 34 proinflammatory cytokines, 13, 14 and a nuclear factor-kappaB (NF-kB) responsive promoter 12 have been predominantly explored for their potential to effectuate arthritis-induced transgene expression. Although several of these appeared applicable for disease-regulated gene therapy, intrinsic properties limit their suitability for minimizing transgene expression under naive conditions. Promoters from APP are in general well-suited for inflammation-induced gene expression, however absolute amounts of transgene expression are far lower than obtained with strong constitutive promoters. 30, 32 To overcome this disadvantage, APP promoters were incorporated in a twocomponent enhancer system. This system relied on APP-regulated expression of the human immunodeficiency (HIV) transactivator of transcription (Tat) that consecutively stimulated protein expression from genes inserted downstream of a HIV long terminal repeat (LTR) promoter. Indeed, this resulted in a gain of transgene expression. However, APP promoter demonstrated leakiness under naive conditions, which led to relatively high background luciferase expression that was equal to, 13 or even surpassed CMV-driven expression. 28 An additional downside of this approach, is the use of the Tat protein, which possesses a large immunogenic potential due to its capacity to regulate numerous host genes involved in cell signaling and translation. 35 An NFkB-responsive promoter showed strong upregulation by proinflammatory cytokines in vitro and in adjuvant arthritis in rat. 12 Strikingly, absolute expression levels exceeded those provided by a constitutive CMV promoter by far, both in vitro and in vivo. Moreover, the same phenomenon was observed for basal levels, indicating that there are substantial amounts of active nuclear NFkB present under naive conditions. Thus, turning off transgene expression under naive conditions by transcriptional control via an NFkB-responsive promoter appears not very feasible. Our results show that the hybrid human IL-1 enhancer/IL-6 promoter emerges as the most likely candidate thus far to achieve low expression under naive conditions in combination with efficacious disease-regulated expression in arthritis. 13, 14 The promoter regions of these interleukin genes were selected based on their crucial role in early onset and development of experimental arthritis. 36, 37 Additionally, microarray analysis of collagen-induced and streptococcal cell wall arthritis revealed a strong correlation of both genes with disease severity and very low expression in naive knee joints (unpublished data). In contrast, APP genes for example complement 3, were originally selected based on the acute-phase response in the liver rather than arthritis models. Although these proteins also show induced production by inflamed RA synovial tissue, 38 they are constitutively expressed under naive conditions in synovial fibroblasts. 39 The latter also holds for NFkB, 40 which explains the relatively high basal levels obtained with these promoters under naive conditions.
An important feature for the development of technologies for arthritis gene therapy would be long-term stable expression in the joint. Recently, it was reported that synovial fibroblasts transduced with lentiviral or adenoviral vectors lost transgene expression in a promoter-independent fashion within 21 days, 10 suggesting that transcriptional control of transgenes would not be beneficial. In our hands, however, we frequently experience rapid loss of transgene expression from constitutively active viral promoters, probably due to in vivo silencing caused by methylation of CpG motifs, 41 histone modifications, 42 cytokine-mediated promoter silencing 43 and vector clearance. 44, 45 Strikingly, knee joints transduced with an IL-1E/IL-6P-Luc vector showed a robust response to inflammatory stimuli up to 90 days after viral transduction (unpublished data). Previously, we demonstrated that there is no significant difference in reduction of viral DNA from transduced-synovium using the viral CMV or cellular IL-1E/IL-6P promoters 13 . It is our hypothesis that cellular promoters are less susceptible to promoter silencing and in fact support long-term expression in synovium as described by others. 8, 9 Our data suggest that disease-regulated transcriptional control of transgene expression is a safer mode of local gene therapy for RA. The therapeutic potential of transgenes under arthritic conditions is retained, while undesirable effects under healthy conditions are effectively minimized. This enables the possible application otherwise disputable biologicals, such as IL-4. Currently, the IL-1E/IL-6P promoter seems very suitable for the development of gene therapy for RA that is based on fine-tuned and restricted expression of therapeutic genes of pleiotrophic nature.
Materials and methods
Animals
Male 10-to 12-week-old DBA-1/J mice were obtained from Janvier (Le Genest Saint Isle, France). C57Bl/6 mice were obtained from Charles River (Sulzfeld, Germany). During adenoviral experiments, mice were housed in low-pressure isolator cages. The animals were fed a standard diet with food and water ad libitum. All in vivo studies complied with national legislation and were approved by local authorities of the Care and Use of Animals with related codes of practice.
Plasmids
Generation of the plasmid pShuttle-IL-1E/IL-6P-Luc, containing the hybrid IL-1 enhancer/IL-6 promoter sequence (IL-1E/IL-6P) was described previously. 13 For cloning, Pfu DNA polymerase (Stratagene, La Jolla, CA, USA) was used. All generated plasmids were verified by sequencing. The plasmid pShuttle-IL-1E/IL-6P-mIL-4-polyA was prepared as follows: the IL-1E/IL-6P promoter was PCR-cloned from pUC18-IL-1E/IL-6P in the XbaI/EcoRV restriction sites of pShuttle (Stratagene, La Jolla, CA, USA). The SV40 polyadenylation signal was PCR-cloned from pShuttle-CMV (Stratagene) in the BglII restriction site of pShuttle-IL-1E/IL-6P. Subsequently, the cDNA of mIL-4 was amplified from the recombinant adenoviral vector Ad5E1mIL-4 (a kind gift from CD Richards, McMaster University, Hamilton, ON, Canada) by using the primers (sense 5 0 -GATATCGCCACCATG GGTCTCAACCCCC-3 0 ; antisense 5 0 -GTCGACCTACGA GTAATCCATTTGC-3 0 ) introducing a Kozak sequence for enhanced translation 46 and inserted into the EcoRV/ SalI sites of pShuttle-IL-1E/IL-6P-polyA generating pShuttle-IL-1E/IL-6P-mIL-4-polyA.
Adenoviral vectors
Replication-deficient adenoviral vectors (E1/E3 deleted) Ad5.IL-1E/IL-6P-Luc, Ad5.IL-1E/IL-6P-mIL-4 and Ad5. dl70-3 were prepared according to the AdEasy system (Stratagene, La Jolla, CA, USA), with the exception that recombinant viral particles were produced in E1 transformed N52E6 amniocyte cells. 47 Replication-deficient (E1 deleted) Ad5.CMV-mIL-4 was produced by infection of N52E6 cells with Ad5E1mIL-4. Viruses were purified by two consecutive CsCl 2 gradient purifications and stored in small aliquots at À80 1C in buffer containing 25 mM Tris, pH 8.0, 5 mM KCl, 0.2 mM MgCl 2 , 137 mM NaCl, 730 mM Na 2 HPO 4 , 0.1% (w v À1 ) ovalbumin and 10% (v v À1 ) glycerol. The infectious particle titer (ffu) was determined by titrating vector stocks on 911 indicator cells and measuring viral capsid protein immunohistochemically 20 h after transduction.
Luciferase measurements
For in vitro evaluation of the effect of mIL-4 on IL-1E/ IL-6P promoter activity, 3T3 cells were seeded at 3 Â 10 4 cells per well in a Krystal 2000 96-wells plate (Thermo Labsystems, Brussels, Belgium) and maintained in Dulbecco's modified Eagle's medium containing 5% fetal calf serum, 1% pyruvate and 40 mg ml À1 gentamycin at 5% CO 2 /37 1C. The day after, cells were transduced with Ad5.IL-1E/IL-6P-Luc in serum-free medium at multiplicity of infection 50 in a total volume of 50 ml for 3 h at 37 1C. Thereafter, medium was replaced for serum- , kind gift of S Gilles, Immunex, Seattle, WA, USA) for 24 h. Luciferase activity was quantified using the Bright-Glo luciferase assay system (Promega, Madison, WI, USA) by adding an equal volume of Bright-Glo to cells lysed in aquadest. Luminescence was measured on the Polarstar Galaxy (BMG, Offenburg, Germany) and expressed as relative light units (RLU) and normalized to total protein content of the cell/tissue extracts.
Induction of collagen-induced arthritis
Bovine collagen type II (CII) was dissolved in 0.05 M acetic acid to a concentration of 2 mg ml À1 and was emulsified in equal volumes of Freud's complete adjuvant (2 mg ml À1 of Mycobacterium tuberculosis strain H37Ra, Difco Laboratories, Detroit, MI, USA). The mice were immunized intradermally at the base of the tail with 100 ml of emulsion (100 mg of bovine CII). On day 21, the mice were given an intraperitoneal booster injection of 100 mg bovine CII dissolved in PBS.
Study protocol and histology
To determine the response of the IL-1E/IL-6P promoter to an immune-mediated inflammation, 10 7 ffu per 6 ml PBS luciferase-encoding adenoviruses were encoding were injected into the knee joints of immunized DBA-1/J mice, one day after they received a CII booster injection. Knee joints were qualitatively scored for inflammation (negative or positive) at the time point of injection. At days 2 and 7 after virus injection, knee joints were qualitatively scored for inflammation and patellae with surrounding tissue were isolated in a standardized manner. 48 For luciferase measurements, patellae were put in 250 ml cell lysis buffer (Promega) and snap frozen in liquid nitrogen. Samples underwent four freeze-thaw cycles and were subsequently centrifuged for 10 min at 13 000 r.p.m. Luciferase activity in the supernatant was determined as described above.
To evaluate effects of mIL-4 expression in naive animals, 10 7 ffu/6 ml PBS adenovirus expressing mIL-4 (Ad5.IL-1E/IL-6P-mIL4 and Ad5.CMV-mIL-4) or an empty control (Ad5.dl70-3) was injected into the knee joints of C57Bl/6 mice. At day 8, mice were killed by cervical dislocation. From four knee joints, patellae washouts were prepared for assessment of mIL-4 levels. Remaining whole knee joints were removed and fixed in 4% paraformaldehyde for 4 days. After decalcification in 5% formic acid, specimens were processed for paraffin embedding. Tissue sections (7 mm) were stained with hematoxylin and eosin (cell influx) or safranin-O (cartilage proteoglycan depletion). Histological changes were scored in the patella/femur region on five semiserial sections of the knee joint, spaced 70 mm apart. Scoring was performed by two observers without knowledge of the group as described before. 49 Histopathological changes were scored using the following parameters. Cartilage depletion, defined as the loss of proteoglycan content, was scored on a scale ranging from 0 to 3 per region, depending on the intensity of staining in the cartilage. Infiltration of cells was scored on a scale of 0-3 (0 ¼ no cells, 1 ¼ mild cellularity, 2 ¼ moderate Disease-regulated IL-4 gene therapy for arthritis J Geurts et al cellularity, 3 ¼ maximal cellularity) , depending on the amount of inflammatory cells in the synovial cavity (exudate) or synovial tissue (infiltrate). 50 Cartilage erosion was graded on a scale of 0-3, ranging from no damage to compete loss of articular cartilage.
To assess the therapeutic efficacy of disease-regulated mIL-4 expression, 10 7 ffu per 6 ml PBS adenovirus encoding IL-1E/IL-6P-mIL-4, CMV-mIL4 (positive control), or empty control (viral control) was injected at day 23 (onset arthritis) in knee joints of immunized DBA-1/J mice without macroscopic signs of arthritis in the paws. Development of arthritis in front and hind paws was macroscopically monitored (scores between 0 and 2) until day 30 (day 7, after intra-articular injection) Consecutively, whole knee joints were removed for histological analysis and cartilage erosion and depletion evaluated as described above.
Murine IL-4 ELISA
Patellae were incubated in RPMI-1640 (Gibco, 200 ml per patella), supplemented with 0.1% bovine serum albumin (Sigma, St Louis, MO, USA), gentamycin (40 mg ml
À1
) and 1% pyruvate for 1 h at room temperature. Subsequently, supernatant was harvested and centrifuged for 5 min at 1000 g. Murine IL-4 levels were determined using the Luminex multianalyte technology, using the BioPlex system in combination with BioPlex Mouse IL-4 Assay (Bio-Rad, Hercules, CA, USA). Cytokines were measured in 50 ml washout medium. The sensitivity of the IL-4 assay was 5 pg ml
.
Statistical analysis
Data values are given as means7s.e.m. and significant differences were determined using Student's t-test or Mann-Whitney U-test, unless stated otherwise. P-values less than 0.05 were regarded as significant.
